Clinical Trial Update: Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating cetuximab for persistent or recurrent cervical cancer has completed, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Cervical Squamous Cell Carcinoma

Drugs mentioned

• ERBITUX (cetuximab)

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2014-06-24